These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39156484)

  • 41. Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.
    Gastine SE; Rauwolf KK; Pieper S; Hempel G; Lehrnbecher T; Tragiannidis A; Groll AH
    Mycoses; 2023 Nov; 66(11):969-976. PubMed ID: 37553971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
    Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
    Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical Analysis of Voriconazole Concentrations in Cerebrospinal Fluid and Blood in Patients with Ryptococcal Meningitis].
    Xiao GR; Liu ZZ; Tang GM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 54(1):192-197. PubMed ID: 36647666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
    Wang X; Zhao J; Wen T; Liao X; Luo B
    Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
    Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
    Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
    Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
    Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inflammation is associated with voriconazole trough concentrations.
    van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of voriconazole hepatotoxicity in a lung transplant patient.
    Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
    Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans.
    Chiller T; Farrokhshad K; Brummer E; Stevens DA
    Med Mycol; 2002 Feb; 40(1):21-6. PubMed ID: 11860010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.
    Tan K; Brayshaw N; Tomaszewski K; Troke P; Wood N
    J Clin Pharmacol; 2006 Feb; 46(2):235-43. PubMed ID: 16432276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.
    Vanstraelen K; Wauters J; Vercammen I; de Loor H; Maertens J; Lagrou K; Annaert P; Spriet I
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6782-9. PubMed ID: 25182655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
    Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
    Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of voriconazole plasma concentrations on treatment response in critically ill patients.
    Ruiz J; Gordon M; Villarreal E; Peruccioni M; Marqués MR; Poveda-Andrés JL; Castellanos-Ortega Á; Ramirez P
    J Clin Pharm Ther; 2019 Aug; 44(4):572-578. PubMed ID: 30851209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
    Yamada T; Mino Y; Naito T; Kawakami J
    J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses.
    Yamada T; Mino Y; Yagi T; Naito T; Kawakami J
    Biol Pharm Bull; 2015; 38(10):1496-503. PubMed ID: 26424015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.
    Amsden JR; Gubbins PO; McConnell S; Anaissie E
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3420-3. PubMed ID: 23629717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic Drug Monitoring of Voriconazole in Patients with End-Stage Liver Disease.
    Wu Z; Jiang M; Yan M; Li G; Zeng Z; Zhang X; Li N; Jiang Y; Gong G; Zhang M
    Ther Drug Monit; 2024 Feb; 46(1):89-94. PubMed ID: 38192036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity.
    Veloso DFMC; Benedetti NIGM; Ávila RI; Bastos TSA; Silva TC; Silva MRR; Batista AC; Valadares MC; Lima EM
    Drug Deliv; 2018 Nov; 25(1):1585-1594. PubMed ID: 30044149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.